For research use only. Not for therapeutic Use.
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF)[1][2].
Andecaliximab increases serum IL-7 levels[1].
Andecaliximab (50 μg/mL; 24 h) reduces phosphorylated SMAD2 (pSMAD2) of ABC-like cell lines[2].
Andecaliximab improves T-cell receptor (TCR) diversity (decreased clonality) within tumor-infiltrating T-cell[1].
Andecaliximab (20 mg/kg; i.p. once) shows the antifibrotic efficacy in a humanized NSG mouse model of idiopathic pulmonary fibrosis[2].
| Catalog Number | I042240 |
| CAS Number | 1518996-49-0 |
| Purity | ≥95% |
| Reference | [1]. Andrew E. Greenstein, et al. Effect of andecaliximab (anti-MMP9) on proteolysis of IL-7 in vitro, TCR diversity in mice, and serum IL-7 in gastric cancer patients in combination with chemotherapy. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. [2]. Espindola MS, et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Feb 15;203(4):458-470. |
